💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010
💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib 20170927